QUESTIONS?

What stage is this

research?                 

Ifetroban research is at the clinical stage, meaning it has advanced to clinical trials in human subjects. Ifetroban has been studied in 27 clinical trials and has been dosed in nearly 1,400 human subjects, including healthy volunteers. There are two on-going clinical trials evaluating ifetroban in systemic sclerosis and in Duchenne muscular dystrophy.

What is the goal

of this study?     

The goal of the FIGHTING FIBROSIS study is to determine if treatment with oral ifetroban is safe and effective to reduce symptoms and slow progression of lung fibrosis in individuals with IPF.

What is ifetroban?

Ifetroban is a medication that comes in a white capsule that is about the length of a dime. Ifetroban inhibits activity of the thromboxane-prostanoid receptor, a receptor found to be linked to fibrosis of several different organs, including the lungs. Previous animal studies investigating ifetroban can be found here.

Who is eligible to

participate?         

Adults 40 years of age or older with a diagnosis of Idiopathic Pulmonary Fibrosis may be eligible to participate. More eligibility information can be found here.

WHAT IS INVOLVED IF I 

DECIDE TO PARTICIPATE?

The FIGHTING FIBROSIS trial involves taking an oral medication once a day for 12 months. You will visit the nearest participating medical center 6 times (3 treatment visits and 3 safety visits) with follow up phone calls in between over a 12 month period.

IS THERE FUNDING TO HELP

WITH TRAVEL COSTS?      

We understand there are costs to you and your family. Cumberland can help defray some of these costs for participation.

WHO CAN I CONTACT TO LEARN MORE

ABOUT PARTICIPATING IN THIS STUDY?

You can contact your doctor or the nearest participating center to you. For further assistance, please call (615) 627-4121 or email FightingFibrosis@cumberlandpharma.com